FDA Approves DEXTROAMPHETAMINE SULFATE EXTENDED-RELEASE — SpecGx LLC
SpecGx LLC announced on Monday that the FDA has approved its new generic drug application (ANDA076353) for extended-release dextroamphetamine sulfate tablets. This approval clears the way for the company to enter the market, signaling increased competition that is expected to drive down pricing for the ADHD treatment segment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed